1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 14:30 ET (18:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.